Headquartered in Canton, Massachusetts, Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
Location: United States, Massachusetts, Canton
Employees: 501-1000
Phone: +1 781-575-0775
Total raised: $250M
Founded date: 1985
Investors 1
| Date | Name | Website |
| - | Avista Cap... | avistacap.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.08.2021 | - | $200M | - |
| 22.05.2017 | - | $20M | Eastward C... |
| 14.04.2016 | - | $30M | - |
Mentions in press and media 15
| Date | Title | Description |
| 29.08.2025 | Engineered Skin Substitutes Edge Closer to Clinical Reality | Researchers are advancing lab-grown skin substitutes that could reshape treatment for burns and chronic wounds. A comprehensive overview of this progress, published in Nature Outlook: Skin, highlights how multilayer grafts are moving closer... |
| 12.11.2024 | Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock | CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound ... |
| 12.03.2024 | Global Skin Grafting Device Market Size to Surpass US$ 1,519.0 Million by 2030 | Exhibiting a CAGR of 7.1% | Global Skin Grafting Device Market size is expected to reach US$ 1,519.0 Million by 2030, from US$ 942.3 Million in 2023, at a CAGR of 7.1% during the forecast period.” — CoherentMIBURLINGAME, CA 94010, UNITED STATES, March 12, 2024 /EINPre... |
| 02.11.2022 | OmniAb Announces Completion of Spin-Off and Business Combination | Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif. (November 1, 2022) – OmniAb, Inc. (NASDAQ: OABI) today announced the co... |
| 09.08.2021 | Organogenesis Holdings Inc :. Announces New $200 Million Credit Agreement with Silicon Valley Bank | CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound ... |
| 04.03.2019 | New Study Shows PuraPly® Antimicrobial Positively Impacts Course of Healing Across Variety of Wound Types | Canton, MA, March 4, 2019 – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and ... |
| 19.08.2018 | Avista Healthcare Public Acquisition Corp. To Combine With Organogenesis | Avista Healthcare Public Acquisition Corp. (NASDAQ :AHPA ), a publicly traded special purpose acquisition company, and Organogenesis Inc. a leading regenerative medicine company focused on the development, manufacture and commercialization ... |
| 23.05.2017 | Term Sheet — Tuesday, May 23 | FALSE START Good morning – today’s column didn’t come together in time. Back tomorrow! • Can China Save Hollywood? Paid Content What you need to know about growing cyberattacks From ExtraHop • The Fortune 100 Companies Doing the Most to Sto... |
| 22.05.2017 | Organogenesis Closes on a $20 Million Facility from Eastward Capital Partners | Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, today closed a $20 million financing facility with Eastward Capital Partners, a leading provider of ventur... |
| 22.05.2017 | Organogenesis Closes on a $20 Million Facility from Eastward Capital Partners | Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, today closed a $20 million financing facility with Eastward Capital Partners, a leading provider of ventur... |
Show more